Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)

NCT01528085 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT01528085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01528085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
March 10, 2020
Enrollment
79 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

philadelphia chromsome positive acute lymphoblastic leukemia